From the other side of the consultation, briefly. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
Following on from rachel_ABQ — and this may be the naive question:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
LipidDoc_ATL said:There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsLipidDoc_ATL said:There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.